BioFluidica, a US-based privately held biotechnology company, announced on Friday that it planning to commercialise the LiquidScan Automated Liquid Biopsy System, a high throughput rare biomarker (circulating tumour cells, exosomes, and cell-free DNA) enrichment solution.

The company has designed and developed an automation-ready liquid biopsy instrument compatible with Hamilton Robotics Microlab STAR series liquid handlers. The commercial version of the LiquidScan system is produced under present Good Manufacturing Practices and includes complete documentation to facilitate clinical application development and clinical trials under EUA and FDA guidelines.

BioFluidica is offering a limited number of systems to certain Core facilities in North America through Early Technology Access Program from fourth quarter of 2021.